Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Atacicept in IgAN - Vera Therapeutics
Frontiers | Systematic Review of Safety and Efficacy of Atacicept in ...
Vera Therapeutics Announces Atacicept Achieved 46%
Vera Therapeutics' Atacicept Shows Promising Results in Phase 2b ORIGIN ...
Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept
New Hope for Kidney Disease: Vera Therapeutics’ Atacicept Advances ...
Vera Therapeutics gets FDA priority review for IgAN drug atacicept ...
Atacicept in LN - Vera Therapeutics
Vera Therapeutics’ Atacicept Shines at ASN Kidney Week 2025 - Investors ...
Vera Therapeutics: Atacicept Cuts Proteinuria 42% in Phase 3 | VERA ...
Vera Therapeutics' Promising Atacicept Drug Targets IgAN | Seeking Alpha
Video: Vera Therapeutics Stock Skyrockets 88% on Atacicept Success!
Atacicept Achieves Endpoints in Phase 3 ORIGIN Trial for IgA Nephropathy
Vera reports long-term atacicept data at Kidney Week 2024 ...
Vera Therapeutics' Atacicept Presentation Design Success | SlideGenius
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN ...
Dr. Barratt Talks Phase 2 Data: Atacicept for IgAN - Patient Worthy ...
Phase 2b Data, Phase 3 Trial Design Provide New Insight into Atacicept ...
Vera Develops 'Engaging Overview' for Atacicept in IgAN, Aims for Q4 ...
Atacicept – Application in Therapy and Current Clinical Research
Atacicept Phase 3 Trial Shows 46% Kidney Disease Improvement in IgA ...
Atacicept 在 IgA 肾病和持续性蛋白尿患者中的随机 II 期 JANUS 研究,Kidney International ...
Atacicept (TACI-Ig) | B Cell Stimulator | MedChemExpress
(PDF) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
atacicept | PDF | Medical Specialties | Clinical Medicine
Vera’s Atacicept Excels in IgA Nephropathy Trial | Perigon
Frontiers | Kinetics of free and ligand-bound atacicept in human serum
Atacicept for IgA nephropathy succeeds in phase III trial ...
Population pharmacokinetics of atacicept in systemic lupus ...
Atacicept Shot Significantly Reduces Proteinuria in IgA Nephropathy: NEJM
| Hypothetical model for the binding of belimumab and atacicept to ...
Atacicept for IgA Nephropathy: Long-Term Results from the ORIGIN Phase ...
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
Atacicept Significantly Reduces Proteinuria in IgA Nephropathy: Phase 3 ...
Kinetics of free and ligand-bound atacicept in human serum - Abstract ...
Atacicept Delivers Remarkable Phase 3 Data for IgA Nephropathy
Study on the Effects of Atacicept in Adults with IgA Nephropathy
(PDF) Population pharmacokinetics of atacicept in systemic lupus ...
(PDF) Systematic Review of Safety and Efficacy of Atacicept in Treating ...
(PDF) Atacicept in combination with MMF and corticosteroids in lupus ...
Atacicept in combination with MMF and corticosteroids in lupus ...
Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and ...
Atacicept prevents B cell repopulation but not isotype switching or ...
10亿美元分子：Vera大涨49%，Atacicept治疗IgA肾病2b期临床成功 Armstrong 2023年1月25日， Vera ...
Science • Vera Therapeutics
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN ...
Atacicept: targeting B cells in multiple sclerosis - PMC
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase ...
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b ...
Vera Therapeutics Announces Positive Week 36 Efficacy and
Vera Therapeutics: Waiting For A Pullback (NASDAQ:VERA) | Seeking Alpha
Vera Therapeutics Presents Positive 72-Week Data Showing
Vera Therapeutics Shares Jump 80% on Strong Phase 3 Trial Results for ...
Vera Therapeutics Receives Priority Review for Atacicept, Shares Advance
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid ...
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial ...
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug ...
Vera Therapeutics In-Person R&D Day: Week 72 Data from Phase 2b ORIGIN ...
Vera Therapeutics Releases 36 Week Interim Analysis of
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety ...
Vera’s Phase IIb OLE trial gives extra confidence for Phase III IgAN trial
I’m thrilled to join the team at Vera Therapeutics and excited for the ...
Results of Open-label Extension of the ORIGIN Study - Explore the ...
© 2023 VERA THERAPEUTICS, INC.
持久缓解近2年，潜在“功能性治愈”肾病！突破性疗法有望明年递交上市申请_腾讯新闻
A phase 2b, randomized, double-blind, placebo-controlled, clinical ...
It is great to see success from Atacicept. Great work Vera taking this ...
Behind The Volatility Of Vera Therapeutics (NASDAQ:VERA) | Seeking Alpha
(PDF) Atacicept: Targeting B cells in multiple sclerosis
WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of ...
In-Person R&D Day: Week 72 Data from Phase 2b ORIGIN Clinical Trial of ...
WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ...
Vera Therapeutics, Inc. on LinkedIn: The role of BAFF and APRIL in IgA ...
Atacicept: What is it and is it FDA approved? - Drugs.com
This Biotech Refused to Quit for 25 Years — Now PTC Therapeutics (PTCT ...
Abatacept Mechanism of Action: Concordance With Its Clinical Profile ...
Vera Therapeutics Announces Appointment of Industry
